Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 24-30

  Luyt, Charles Edouard ^a   Meddahi Pellé, Anne ^a   Ho Tin Noe, Benoit ^a   Colliec Jouault, Ylvia ^b   Guezennec, Jean ^b   Louedec, Liliane ^a   Prats, Hervé ^c   Jacob, Marie Paule ^a   Osborne Pellegrin, Mary ^a   Letourneur, Didier ^a   Michel, Jean Baptiste ^a,d  

^a BICHAT HOSPITAL   (France)

^b Ress Vivantes Valorisation Prod   (France)

^c Department of Oncology   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; FIBROBLAST GROWTH FACTOR 2; FUCOIDIN; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; HINDLIMB; LIMB ISCHEMIA; METABOLIC ACTIVATION; MUSCLE BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REVASCULARIZATION; SMOOTH MUSCLE FIBER; STEM CELL; STROMA CELL; VASCULAR ENDOTHELIUM;

ANIMALS; ANTICOAGULANTS; CAPILLARIES; CELLS, CULTURED; CHEMOKINES, CXC; DISEASE MODELS, ANIMAL; HINDLIMB; ISCHEMIA; MALE; MATRIX METALLOPROTEINASE 9; MOLECULAR WEIGHT; MYOCYTES, SMOOTH MUSCLE; PERFUSION; PHOSPHORYLASES; POLYSACCHARIDES; RATS; RATS, WISTAR; THYMIDINE;

EID: 0037380038     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.046144     Document Type: Article

References (50)

1. Alroy J, Goyal V, and Skutelsky E (1987) Lectin histochemistry of mammalian endothelium. Histochemistry 86:603-607.
2. Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, Montes M, Virelizier JL, Delepierre M, Baleux F, Lortat-Jacob H, and Arenzana-Seisdedos F (1999) Stromal cell-derived factor-1α associates with heparan sulfates through the first β-strand of the chemokine. J Biol Chem 274:23916-23925.
3. Aviezer D, Levy E, and Safran M (1994) Differential structural requirement of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem 269:114-121.
4. Battle T, Arnal J, Challah M, and Michel J (1994a) Selective isolation of rat aortic wall layers and their cell types in culture. Tissue Cell 26:943-955.
5. Battle T, Arnal JF, and Michel JB (1994b) Hyperproliferation of aortic smooth muscle cells and fibroblasts from young SHR rats is not shared by endothelial cells. Clin Exp Pharmacol Physiol 21:981-989.
6. Belford D, Hendry I, and Parish C (1993) Investigation of the ability of several naturally occurring and synthetic polyanions to bind and to potentiate the biological activity of acidic fibroblast growth factor. J Cell Physiol 157:184-189.
7. Bjornsson TD, Dryjski M, Tluczek J, Mennie R, Ronan J, Mellin TN, and Thomas KA (1991) Acidic fibroblast growth factor promotes vascular repair. Proc Natl Acad Sci USA 88:8651-8655.
8. Burgess WH and Maciag T (1989) The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58:575-606.
9. Carlson BM and Gutmann E (1975) Regeneration in free grafts of normal and denervated muscles in the rat: morphology and histochemistry. Anat Rec 183:47-62.
10. Chevolot L, Foucault A, Chaubet F, Kervarec N, Sinquin C, Fisher AM, and Boisson-Vidal C (1999) Further data on the structure of brown seaweed fucans: relationships with anticoagulant activity. Carbohydr Res 319:154-165.
11. Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, and Giménez-Gallego G (1991) Hypotensive activity of fibroblast growth factor. Science (Wash DC) 254:1208-1210.
12. Deux J-F, Meddahi-Pellé A, Le Blanche AF, Feldman LJ, Colliec-Jouault S, Bree F, Boudghene F, Michel J-B, and Letourneur D (2002) Low molecular weight fucoidan prevents neointimal hyperplasia in rabbit iliac artery in-stent restenosis model. Arterioscler Thromb Vasc Biol 22:1604-1609.
13. Frenette PS and Weiss L (2000) Sulfated glycans induce rapid hematopoietic progenitor cell mobilization: evidence for selectin-dependent and independent mechanisms. Blood 96:2460-2468.
14. Giraux J, Matou S, Bros A, Tapon-Bretaudiere J, Letourneur D, and Fischer A (1998) Modulation of human endothelial cell proliferation and migration by fucoidan and heparin. Eur J Cell Biol 77:352-359.
15. Goncalves LM (1998) Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Rev Port Cardiol 17:II11-20.
16. Gospodarowicz D (1974) Localisation of fibroblast growth factor and its effects alone and with hydrocortisone on 3T3 cell growth. Nature (Lond) 249:123-127.
17. Haroun-Bouhedja F, Ellouali M, Sinquin C, and Boisson-Vidal C (2000) Relationship between sulfate groups and biological activities of fucans. Thromb Res 100:453-459.
18. Jacob MP, Cazaubon M, Scemama A, Prie D, Blanchet F, Guillin MC, and Michel JB (2002) Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation 106:535-538.
19. Lazarous DF, Shou M, Stiber JA, Dadhnia DM, Thirumurti V, Hodge E, and Unger EF (1997) Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 36:78-85.
20. Lefaucheur JP and Sebille A (1995) Basic fibroblast growth factor promotes in vivo muscle regeneration in murine muscular dystrophy. Neurosci Lett 202:121-124.
21. Lindner V and Reidy MA (1991) Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 88:3739-3743.
22. Logeart D, Prigent-Richard S, Boisson-Vidal C, Chaubet F, Durand P, Jozefonvicz J, and Letourneur D (1997a) Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. II. Degradation and molecular weight effect. Eur J Cell Biol 74:385-390.
23. Logeart D, Prigent-Richard S, Jozefonvicz J, and Letourneur D (1997b) Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. I. Comparison with heparin for antiproliferative activity, binding and internalization. Eur J Cell Biol 74:376-384.
24. Lortat-Jacob H, Grosdidier A, and Imberty A (2002) Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Sci USA 99:1229-1234.
25. Luyt CE, Lepailleur-Enouf D, Gautier CJ, Valdenaire O, Steg PG, and Michel JB (2000) Involvement of the endothelin system in experimental critical hindlimb ischemia. Mol Med 6:947-956.
26. Maciag T, Mehiman T, Friesel R, and Schreiber A (1984) Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science (Wash DC) 225:932-935.
27. Matou S, Helley D, Chabut D, Bros A, and Fischer A (2002) Effect of fucoidan on fibroblast growth factor-2-induced angiogenesis in vitro. Thromb Res 106:213.
28. McCaffrey TA, Falcone DJ, Borth W, Brayton CF, and Weksler BB (1992) Fucoidan is a non-anticoagulant inhibitor of intimal hyperplasia. Biochem Biophys Res Commun 184:773-781.
29. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, and Hornebeck W (1995) Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation. Biochimie 77:703-706.
30. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, and Hornebeck W (1996) FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol 18:141-145.
31. Millet J, Jouault SC, Mauray S, Theveniaux J, Sternberg C, Boisson-Vidal C, and Fischer AM (1999) Antithrombotic and anticoagulant activities of a low molecular weight fucoidan. Thromb Haemost 81:391-395.
32. Mirshahi F, Pourtau J, Li H, Muraine M, Trochon V, Legrand E, Vannier J, Soria J, Vasse M, and Soria C (2000) SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 99:587-594.
33. Nardella A, Chaubet F, Boisson-Vidal C, Blondin C, Durand P, and Jozefonvicz J (1996) Anticoagulant low molecular weight fucans produced by radical process and ion exchange chromatography of high molecular weight fucans extracted from the brown seaweed Ascophyllum nodosum. Carbohydr Res 289:201-208.
34. Nilsson GE, Tenland T, and Obert PA (1980) Evaluation of a laser Doppler flowmeter for measurement of tissue blood flow. IEEE Trans Biomed Eng 27:597-604.
35. Patry V, Bugler B, Amalric F, Prome JC, and Prats H (1994) Purification and characterization of the 210-amino acid recombinant basic fibroblast growth factor form (FGF-2). FEBS Lett 349:23-28.
36. Pellegrini L (2001) Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 11:629-634.
37. Religa P, Kazi M, Thyberg J, Gaciong Z, Swedenborg J, and Hedin U (2000) Fucoidan inhibits smooth muscle cell proliferation and reduces mitogen-activated protein kinase activity. Eur J Vasc Endovasc Surg 20:419-426.
38. Roghani M, Mansukhani A, and Dell'Era P (1994) Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem 269:3976-3984.
39. Rosengart TK, Budenbender KT, Duenas M, Mack CA, Zhang QX, and Isom OW (1997) Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J Vasc Surg 26:302-312.
40. Rusnati M and Presta M (1996) Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int J Clin Lab Res 26:15-23.
41. Sadir R, Baleux F, Grosdidier A, Imberty A, and Lortat-Jacob H (2001) Characterization of the stromal cell-derived factor-1a-heparin complex. J Biol Chem 276: 8288-8296.
42. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ, and Oppenheim JJ (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α. Am J Pathol 154:1125-1135.
43. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, and Tosato G (2002) Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 99:2703-2711.
44. Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, and Simons M (1996) Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 120:182-188.
45. Shou M, Thirumurti V, Sharmini Rajanayagam MA, Lazarous DF, Hodge E, Stiber JA, Pettiford M, Elliott E, Shah SM, and Unger EF (1997) Effects of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels. J Am Coll Cardiol 29:1102-1106.
46. Sweeney E, Lortat-Jacob H, Priestley GV, Nakamoto B, and Papayannopoulou T (2002) Sulfated polysaccharides increase plasma level of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 99:44-51.
47. Sweeney E, Priestley GV, Nakamoto B, Collins RG, Beaudet A, and Papayannopoulou T (2000) Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence. Proc Natl Acad Sci USA 97:6544-6549.
48. Whalen G, Shing Y, and Folkmann J (1989) The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1:157-164.
49. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, Sugimoto T, Kaji K, Utsuyama M, Kurashima C, and Ito H (1992) Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science (Wash DC) 257:1401-1403.
50. Yang HT, Deschenes MR, Ogilvie RW, and Terjung RL (1996) Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ Res 79:62-69.